 |
Photo = Celltrion |
[Alpha Biz= Kim Jisun] Celltrion’s oncology products continue to maintain leading market share in Japan, one of the most important pharmaceutical markets in Asia.
According to pharmaceutical market research firm IQVIA and local data released on March 16, Bevzelma (bevacizumab), a treatment for metastatic colorectal cancer and breast cancer, recorded a 58% market share in Japan as of December last year. The product has sustained its growth momentum since surpassing the 50% market share mark in September.
Earlier, Herzuma (trastuzumab), a treatment for breast and gastric cancers, also demonstrated strong performance, capturing a 76% market share in Japan during the same period and firmly establishing its dominance in prescriptions.
First launched in Japan in 2019, Herzuma overtook the originator product Herceptin in prescription share for the first time in the second quarter of 2021. Since then, it has maintained the top prescription position for approximately four and a half years.
Beyond oncology treatments, Celltrion’s autoimmune disease therapies are also achieving notable results in the Japanese market. Remsima (infliximab) and Yuflyma (adalimumab) recorded market shares of 43% and 17%, respectively, the highest prescription volumes among biosimilar products in Japan.
Celltrion’s performance in Japan is expected to continue. The launch of SteQeyma (ustekinumab) in August last year has further strengthened the company’s product portfolio, increasing marketing synergies.
In addition, Celltrion plans to introduce another autoimmune disease therapy, Avtozma (tocilizumab), to the Japanese market in the second quarter of this year, further expanding its lineup of high-value products.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
